Raloxifene augmentation in postmenopausal women with schizophrenia has shown promising results. Younger patients diagnosed as treatment-resistant schizophrenia and treated with raloxifene (120 mg/day) have reported significant improvement in symptoms. This case highlights how raloxifene, a selective estrogen receptor modulator (SERM), can play a major role in alleviating positive and negative symptoms in postmenopausal women with treatment-resistant schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00737-015-0545-9 | DOI Listing |
Publication Analysis
Top Keywords
treatment-resistant schizophrenia
12
postmenopausal women
8
raloxifene
4
raloxifene trial
4
trial postmenopausal
4
postmenopausal woman
4
woman treatment-resistant
4
schizophrenia
4
schizophrenia raloxifene
4
raloxifene augmentation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!